Opinion|Videos|September 11, 2024
Understanding Oligometastatic Disease in Prostate Cancer: Insights from PSMA PET Imaging
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Key opinion leaders examine the role of advanced imaging agents, particularly PSMA PET and other radiotracers, in identifying and defining oligometastatic disease in patients with prostate cancer.
Advertisement
Video content above is prompted by the following:
- How do imaging agents, such as PSMA PET or other radiotracers, contribute to the detection and characterization of oligometastasis in prostate cancer patients?
Advertisement
Related to this article
Uptunity | Aneurysm reportedly identifies suspected saccular brain aneurysms larger than 3 mm on head CTA and provides quantitative comparison between exams to assess changes in known aneurysms over time.
Through enhanced insights into atherosclerotic disease, complex coronary lesions and coronary stents, photon-counting CT provides an anatomical roadmap that may improve outcomes for interventional procedures.
The PSMA PET radiopharmaceutical 64Cu-SAR-bisPSMA, which previously garnered two FDA fast track designations, more than doubled the detection of PCa lesions in comparison to 68Ga-PSMA-11 in the phase II Co-PSMA trial.
The mobile X-Ray unit DR 100s Pro reportedly offers an array of attributes to facilitate workflow efficiencies and quality imaging.
In comparison to the RECIST 1.1 criteria, use of the mpMRI-based NacBI-RADS system for evaluating response to neoadjuvant chemotherapy (NAC) for breast cancer offered an 8 percent higher sensitivity and over 26 percent higher specificity.
A high glandular tissue component on pre-op breast ultrasound may significantly elevate the risk of recurrence for ipsilateral or contralateral breast cancer, according to a newly published study.
Effective January 1, 2027, use of the QTscan in outpatient diagnostic exams will be reimbursable with the CPT code 1079T.
In a recent interview, Carolynn DeBenedectis, MD, discussed the utility of AI-enabled slab reconstruction for interpretation of digital breast tomosynthesis (DBT) and new research showing a 13 percent reduction in reading time.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears CTA-Based AI Software for Brain Aneurysm Detection and Follow-Up
2
Will PCCT Lead the Next Revolution in Interventional Cardiology?
3
FDA Issues Breakthrough Therapy Designation for Emerging PSMA PET Agent in Men with Suspected PCa Recurrence
4
Agfa Radiology to Introduce AI-Powered DR 100s Pro X-Ray Platform at RSNA
5